INS and obesity disorder: In recent clinical trials, weekly administration of tirzepatide (15 mg) for 72 weeks has shown substantial and sustained reductions in body weight (> 25%) in 36.2% of obese patients recruited [195], and remarkable glycaemic benefits when compared to insulin degludec in patients with T2D [196]; similar results were achieved previously only by bariatric surgery, the first strategy with high remission rate of both obesity and T2D, but with several post-intervention complications [197].